|
|
Post by fiddler on Oct 9, 2016 10:53:29 GMT -5
Will the patent affect health insurance?
|
|
|
|
Post by centralcoastinvestor on Oct 9, 2016 14:50:19 GMT -5
Will the patent affect health insurance? Could you elaborate on this question? In what way would a patent affect insurance coverage? |
|
|
|
Post by esstan2001 on Dec 23, 2016 19:33:51 GMT -5
finance.yahoo.com/news/something-strange-going-oral-insulin-174117941.htmlSomething Strange Is Going On With Oral Insulin GuruFocus.com December 23, 2016 - By Matt Winkler Something is rotten in the state of Denmark. Shakespearean quotes are often limited in their dramatic effect, but in this case the line from "Hamlet" can be taken a bit more literally. Nearly two months month ago on the day before Halloween, Danish diabetes giant Novo Nordisk A/S (NVO) (OCSE:NOVO B) unexpectedly called it quits on what was becoming a more and more promising oral insulin formulation. ... you read this (I mean the whole story in the link) and realize what a threat early insulin use is to the revenues of the big drug co's... and their apparent willingness to bury advances that threaten the status quo.
|
|
|
|
Post by onemann on Dec 23, 2016 21:02:49 GMT -5
Good post Esstan. It was an interesting article. I hope in our case good prevails and helps all diabetics with their disease and the evil greedy companies lose thier a$$ for sandbagging or go to jail.
|
|
|
|
Post by surplusvalue on Dec 23, 2016 23:21:11 GMT -5
finance.yahoo.com/news/something-strange-going-oral-insulin-174117941.htmlSomething Strange Is Going On With Oral Insulin GuruFocus.com December 23, 2016 - By Matt Winkler Something is rotten in the state of Denmark. Shakespearean quotes are often limited in their dramatic effect, but in this case the line from "Hamlet" can be taken a bit more literally. Nearly two months month ago on the day before Halloween, Danish diabetes giant Novo Nordisk A/S (NVO) (OCSE:NOVO B) unexpectedly called it quits on what was becoming a more and more promising oral insulin formulation. ... you read this (I mean the whole story in the link) and realize what a threat early insulin use is to the revenues of the big drug co's... and their apparent willingness to bury advances that threaten the status quo. Not surprised at all. Interesting and insightful article which reinforces what I said about illness being a cash cow and in other posts as to why MNKD is a stock targeted to .05 cents with over 100 million shorts since it is a disruptive threat to big pharma. "So by comparison they will not achieve what Afrezza can, but what may be important to them is that it creates an entire new space for profits and entrenching the same old insulins. Its a win win for both sides (the technology companies and big pharma) but not for the patients; it keeps them dependent and ill. It leads the patients to believe that the best they can hope for is a reduced number of injections instead of an actual improvement in their health...I'm afraid they will do what they are trying to do and continue to be dismissive of Afrezza. They will reduce injections by more careful monitoring. This is for big pharma much cheaper than to try to continue to compete with each other by trying to develop better insulins and get them approved. Afrezza is a disruptive technology that threatens big pharma ..... Illness is a cash cow. "See here my full post in Sept : mnkd.proboards.com/thread/6214/me?page=5thIn this case my Sept post was about the new cgm and cloud technology implementation not being used for helping to make patients healthy but rather to keep them dependent. Burying these other promising developments as cited in the article and burying Afrezza amounts to the same thing. Keep the same old insulins dominant and just dress them up with new technological supports so they can keep the cash/profits flowing long term. |
|
|
|
Post by lakon on Dec 27, 2016 10:10:29 GMT -5
You may be on to something here. Of course, if THEY fail and MNKD succeeds, THEY are washed up and MNKD is bigger than ever imagined by most. Just a thought...
|
|
|
|
Post by mango on Feb 3, 2017 19:58:44 GMT -5
MannKind Oral Inhalation Worldwide Issued Patents
• 918 patents encompassing powders, devices and manufacturing technologies
• 510 patents protecting AFREZZA® and related technologies
• 188 patents related to formulations and methods of use
• 358 patents related to inhaler device technologies (utility and designs)
• 82 patents related to process and manufacturing technologies
• 114 patents related to powder dispensing/filling technologies
• 48 patents protecting inhaler support technologies, e.g., BluHale®, MIDAS
• 90 patents related to miscellaneous technologies and uses, e.g., GLP‐1, pain peptides, triptans, etc.
• > 600 pending patent applications in multiple patent families directed to various technologies, e.g., alternate inhalers, new powders, methods of use, etc.
|
|
|
|
Post by dreamboatcruise on Feb 3, 2017 20:54:06 GMT -5
mango... These may all be very good to protect anyone from trying to copy Afrezza, but so far we are protected from that because anyone would be crazy to put the money into replicating a drug that isn't selling. There are many powder based drugs on the market, and MNKD hasn't licensed any of these technologies. It may seem like a huge number of patents, but it seems they don't extend beyond Afrezza and TS. If there isn't any double counting in that list of patents it is probably $30M at least sunk into costs. I'm sure we'd be much better off to have 1/3 that number and have $20M more in the bank.
|
|
|
|
Post by mnkdfann on Feb 3, 2017 21:22:56 GMT -5
MannKind Oral Inhalation Worldwide Issued Patents• 918 patents encompassing powders, devices and manufacturing technologies
• 510 patents protecting AFREZZA® and related technologies
• 188 patents related to formulations and methods of use
• 358 patents related to inhaler device technologies (utility and designs)
• 82 patents related to process and manufacturing technologies • 114 patents related to powder dispensing/filling technologies • 48 patents protecting inhaler support technologies, e.g., BluHale®, MIDAS • 90 patents related to miscellaneous technologies and uses, e.g., GLP‐1, pain peptides, triptans, etc. • > 600 pending patent applications in multiple patent families directed to various technologies, e.g., alternate inhalers, new powders, methods of use, etc. All of that and 10 MNKD shares just might buy you a Triple, Venti, Half Sweet, Non-Fat, Caramel Macchiato. |
|
|
|
Post by bioexec25 on Feb 3, 2017 21:51:35 GMT -5
Feels kinda of like building a wall to keep the scientists in. As long as they are filing they are smiling (regardless of commercial value).
|
|
|
|
Post by mango on Feb 3, 2017 22:27:20 GMT -5
mango ... These may all be very good to protect anyone from trying to copy Afrezza, but so far we are protected from that because anyone would be crazy to put the money into replicating a drug that isn't selling. There are many powder based drugs on the market, and MNKD hasn't licensed any of these technologies. It may seem like a huge number of patents, but it seems they don't extend beyond Afrezza and TS. If there isn't any double counting in that list of patents it is probably $30M at least sunk into costs. I'm sure we'd be much better off to have 1/3 that number and have $20M more in the bank. In this keynote speech by the late, Mr. Alfred Mann at the 2010 Johns Hopkins University CBID Design Day, he gives a great example of what a company is willing to do (pay) to dissolve an innovative threat that could potentially compete with their market space. m.youtube.com/watch?v=muBuxTqxmQoI am not surprised by your comment, it is that perhaps you have not yet realized the vast differences that separate MannKind from BP. There is a reason they protect their IP like they do. The trend, actually, has risen significantly with diketopiperazine research in just the past few years. It has nothing to do with Afrezza, per say, but everything to do with the stamped potential. When little ole MannKind can do this, just imagine for a moment substituting X for insulin. Companies are hit by an overwhelming huge wave of panic when the onset of innovation threatens their bottom line (money).  |
|
|
|
Post by gamblerjag on Feb 4, 2017 1:18:33 GMT -5
If Matt was ever asked the question.. what do you think MNKD is worth including all components. ............. could he give an answer.. ? I understand that they can't say what they have ever been offered.. if they ever were offered anything for Afrezza or the Company. I know speculation is that they were .. not sure Matt said that he had some low ball offers but not sure if that was from a BP to buy Afrezza or MNKD.. but could Matt or Mike ever say what they think the Co. is worth....?? that would give us some indication on what they expect to get or hope to get some day if they sold either Afrezza or MNKD.. just curioius.. Thanks.
|
|
|
|
Post by mango on Feb 4, 2017 1:48:25 GMT -5
If Matt was ever asked the question.. what do you think MNKD is worth including all components. ............. could he give an answer.. ? I understand that they can't say what they have ever been offered.. if they ever were offered anything for Afrezza or the Company. I know speculation is that they were .. not sure Matt said that he had some low ball offers but not sure if that was from a BP to buy Afrezza or MNKD.. but could Matt or Mike ever say what they think the Co. is worth....?? that would give us some indication on what they expect to get or hope to get some day if they sold either Afrezza or MNKD.. just curioius.. Thanks. I would have to guess that would not be a good idea, if it were, every company would be boasting it. I could see many lawsuits. IMO. |
|
|
|
Post by centralcoastinvestor on Feb 4, 2017 2:44:00 GMT -5
I still believe the longer Mnkd survives, the greater threat they become. It has been a brutal ride so far. The shorts have been relentless since I have owned the stock since 2007. They just never go away. Call me paranoid, but I think some BP is backing the short effort. And I believe that someday we will be very thankful we have all of those patents to protect Afrezza and all of the future Technosphere products.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 4, 2017 7:40:48 GMT -5
I still believe the longer Mnkd survives, the greater threat they become. It has been a brutal ride so far. The shorts have been relentless since I have owned the stock since 2007. They just never go away. Call me paranoid, but I think some BP is backing the short effort. And I believe that someday we will be very thankful we have all of those patents to protect Afrezza and all of the future Technosphere products. Shorts stopping PWD from Afrezza? |
|
